Abstract: Acetobacter strains are identified as stable under agitated culture conditions and exhibit substantially reduced gluconic and keto-gluconic acids production. A method and media for producing bacterial cellulose under agitated culture conditions resulting in sustained production over an average of 70 hours of at least 0.1 g/liter per hour are achieved. A unique reticulated cellulose product is produced using the methods and conditions claimed, and may be converted to of a sheet characterized by substantial resistance to densification and great tensile strength when produced by sheet forming means. Preferred Acetobacter strains are ATCC Nos. 53264, 53263 and 53524.
Type:
Grant
Filed:
June 1, 1993
Date of Patent:
August 6, 2002
Assignee:
CP Kelco U.S., Inc.
Inventors:
Arie Ben-Bassat, Robert Bruner, Sharon Shoemaker, Yehoshua Aloni, Harry Wong, Donald C. Johnson, Amar N. Neogi
Abstract: A method and media for producing bacterial cellulose under agitated culture conditions resulting in sustained production over an average of 70 hours of at least 0.1 g/liter per hour are achieved. A unique reticulated cellulose product is produced using the methods and conditions claimed, and may be converted to of a sheet characterized by substantial resistance to densification and great tensile strength when produced by sheet forming means. Acetobacter strains are identified as stable under agitated culture conditions and exhibit substantially reduced gluconic and keto-gluconic acids production.
Type:
Grant
Filed:
June 1, 1993
Date of Patent:
December 11, 2001
Assignee:
CP Kelco U.S., Inc.
Inventors:
Arie Ben-Bassat, Robert Bruner, Sharon Shoemaker, Yehoshua Aloni, Harry Wong, Donald C. Johnson, Amar N. Neogi
Abstract: The present invention provides methods for measuring endogenous heparin in a mammal at levels that were previously undetectable. The present invention further features methods for assessing the risk for and assessing the progression of atherosclerosis and methods for treating or inhibiting the progression of atherosclerosis. The invention also features methods for monitoring plasma heparin levels in subjects undergoing heparin treatment. Additionally, the present invention provides kits for assaying for heparin in biological samples.
Abstract: The subject invention provides methods and kits for detecting increased bone resorption in patients. These methods and kits use chondroitin sulfate, a glycosaminoglycan, as a marker for bone resorption. Levels of chondroitin sulfate are detected in samples of urine or serum taken from patients. Measurements of chondroitin sulfate levels are made by methods such as fluorophore-assisted carbohydrate electrophoresis (FACE). Knowledge of increased bone resorption rates is useful in diagnosis of bone disorders such as osteoporosis.